Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma 17Mesothelioma, Malignant 15Solid Tumor 10Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumors 8Melanoma 6Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Advanced Solid Tumor 5Solid Tumors 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Advanced or Metastatic Solid Tumors 3Turcot syndrome 2Stomach Neoplasms 2Neoplasm Metastasis 2Malignant Solid Tumor 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 3vadimezan 1malic acid 1Valproic Acid 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor Malignancies × Nivolumab × Other solid neoplasm × Clear all
NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

University of Kansas Medical Center

Phase 3 Recruiting
192 enrolled
Other solid neoplasm

Solid Tumor Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡